More benefits seen with earlier Encelto treatment for macular telangiectasia type 2

LONG BEACH, Calif. — Patients treated with Encelto who had smaller baseline ellipsoid zone area loss had better treatment response, according to a post hoc analysis presented at the American Society of Retina Specialists annual meeting.Encelto (revakinagene taroretcel-lwey, Neurotech Pharmaceuticals) was approved in March by the FDA for the treatment of macular telangiectasia type 2